Autoimmune diseases
a global public
Healthcare Issue
with unmet medical needs

The number of patients affected by autoimmune diseases is increasing worldwide. The treatment of autoimmune diseases is costly and  a serious concern to healthcare system.

Kinoid® technology:
An innovative
therapeutic Approach

Our Kinoid®  technology is an alternative to monoclonal antibodies.

Our ambition:
to develop accessible treatments

Our goal is to provide patients with less costly, more convenient and safe treatments, without hospitalization.

About Neovacs

Neovacs is a French biotech company focused on the development of Kinoids®, therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.

Discover our Kinoids®

Therapeutic vaccines to treat several chronic diseases:

IFN Kinoide
and LUPUS

Lupus is a chronic autoimmune disease, which can affect several organs. Currently in phase IIb clinical study in US, EU, Asia and South-America.

show more

IFN KINOID AND DERMATOMYOSITIS

Dermatomyositis is an orphan disease which can affect skin and muscles. Currently in phase IIa clinical study in EU.

show more

IFN KINOID AND TYPE I DIABETES

This disease is characterized by a destruction of the pancreas, its prevalence has increased 3 to 4% per year over the past two decades. Currently in preclinical Proof of concept stage.
show more

VEGF KINOID
AND CANCERS

Preclinical stage ongoing in collaboration with the Sunnybrook Research Institute of Toronto, Canada.

show more

IL-4 /IL-13 KINOID AND ALLERGIES

Neovacs’ technology has the potential to treat patients suffering from environmental and food allergies.

show more

Applying vaccine technology to treat chronic diseases

To better understand Neovacs’ Kinoid® technology, we invite you to watch this video.

More details

Why should you invest in Neovacs ?

go to the investors section

News

Entreprise du jour: Néovacs annonce les...

Entretien avec Miguel Sieler, président directeur général de Néovacs. – Intégrale Bourse,...

imagespt99l2hs

Tête à tête de la finance

ITW de Miguel Sieler, directeur Général de Néovacs

bouriser (2)

Des résultats cliniques de bonne qualité...

La biotech a communiqué des résultats de phase II b qui étaient très attendus dans l’indication du...

investir1

INTERVIEW WITH PR. JACQUES BANCHEREAU

The therapeutic approach of Neovacs explained by Prof. Jacques Banchereau

ITW PR BANCHEREAU (2)

Follow us on Twitter